- Home
- MDAI vs NRXP Comparison
MDAI vs NRXP Comparison
Compare MDAI & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDAI | NRXP |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 63.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MDAI | NRXP |
|---|---|---|
| Price | $1.61 | $2.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.25 | ★ $30.50 |
| AVG Volume (30 Days) | 340.2K | ★ 461.9K |
| Earning Date | 11-11-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $23,168,000.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $1.17 |
| 52 Week High | $3.25 | $6.01 |
Technical Indicators
Market Signals| Indicator | MDAI | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 37.62 |
| Support Level | $1.63 | $2.22 |
| Resistance Level | $1.76 | $2.39 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 52.31 | 4.26 |
Price Performance
Historical ComparisonAbout MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.